نتائج البحث

Impaired FADD/BID signaling mediates cross-resistance to immunotherapy in Multiple Myeloma.

• Authors : Munawar, Umair¹ (AUTHOR); Zhou, Xiang¹ (AUTHOR); Prommersberger, Sabrina¹ (AUTHOR)

• Source: Communications Biology. 12/21/2023, Vol. 6 Issue 1, p1-9. 9p.

تفاصيل العنوان

Does medication-related osteonecrosis of the jaw affect survival of patients with Multiple Myeloma?: Exploring a large single center database using artificial intelligence.

• Authors : Bittrich, Max; Hetterich, Regina; Solimando, Antonio G.

Subjects: MULTIPLE myeloma; ARTIFICIAL intelligence; DATABASES

• Source: Clinical & Experimental Medicine; Dec2023, Vol. 23 Issue 8, p5215-5226, 12p

تفاصيل العنوان

Neurofilament light chain levels indicate acute axonal damage under bortezomib treatment.

• Authors : Cebulla, Nadine; Schirmer, Daniel; Runau, Eva

Subjects: CYTOPLASMIC filaments; BORTEZOMIB; CYTOSKELETAL proteins

• Source: Journal of Neurology; Jun2023, Vol. 270 Issue 6, p2997-3007, 11p

تفاصيل العنوان

Bortezomib induced peripheral neuropathy and single nucleotide polymorphisms in PKNOX1.

• Authors : Zhou, Xiang; Han, Seungbin; Cebulla, Nadine

Subjects: SINGLE nucleotide polymorphisms; PERIPHERAL neuropathy; BORTEZOMIB

• Source: Biomarker Research; 5/16/2023, Vol. 11 Issue 1, p1-4, 4p

تفاصيل العنوان

Multiagent therapy with pomalidomide, bortezomib, doxorubicin, dexamethasone, and daratumumab ("Pom‐PAD‐Dara") in relapsed/refractory multiple myeloma.

• Authors : Zhou, Xiang¹ (AUTHOR); Steinhardt, Maximilian J.¹ (AUTHOR); Grathwohl, Denise¹ (AUTHOR)

• Source: Cancer Medicine. Aug2020, Vol. 9 Issue 16, p5819-5826. 8p.

تفاصيل العنوان

Targeting myeloma metabolism: How abnormal metabolism contributes to multiple myeloma progression and resistance to proteasome inhibitors.

• Authors : Zhou X; Molecular Biology Research Center, Department of Biochemistry and Molecular Biology, School of Life Sciences, Central South University, China.; He R

Subjects: Proteasome Inhibitors*/Proteasome Inhibitors*/Proteasome Inhibitors*/pharmacology ; Proteasome Inhibitors*/Proteasome Inhibitors*/Proteasome Inhibitors*/therapeutic use ; Multiple Myeloma*/Multiple Myeloma*/Multiple Myeloma*/drug therapy

• Source: Neoplasia (New York, N.Y.) [Neoplasia] 2024 Apr; Vol. 50, pp. 100974. Date of Electronic Publication: 2024 Feb 16.Publisher: Elsevier Country of Publication: United States NLM ID: 100886622 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

تفاصيل العنوان

Venetoclax salvage therapy in relapsed/refractory multiple myeloma.

• Authors : Steinhardt MJ; Medizinische Klinik und Poliklinik II, Universitätsklinikum Würzburg, Würzburg.; Truger M

Subjects: Multiple Myeloma*/Multiple Myeloma*/Multiple Myeloma*/drug therapy ; Neoplasms, Plasma Cell* ; Sulfonamides*

• Source: Haematologica [Haematologica] 2024 Mar 01; Vol. 109 (3), pp. 979-981. Date of Electronic Publication: 2024 Mar 01.Publisher: Ferrata Storti Foundation Country of Publication: Italy NLM ID: 0417435 Publication Model: Electronic Cited Medium: Internet ISSN:

تفاصيل العنوان

Monoclonal gammopathy of ocular significance (MGOS) – a short survey of corneal manifestations and treatment outcomes.

• Authors : Garderet, Laurent; Al Hariri, Mohammad; Wasielica-Poslednik, Joanna

Subjects: MONOCLONAL gammopathies; PLASMA cell diseases; TREATMENT effectiveness

• Source: Leukemia & Lymphoma; Apr2022, Vol. 63 Issue 4, p984-990, 7p

تفاصيل العنوان

High-dose carfilzomib achieves superior anti-tumor activity over low-dose and recaptures response in relapsed/refractory multiple myeloma resistant to lowdose carfilzomib by co-inhibiting the β2 and β1 subunits of the proteasome complex.

• Authors : Zhou X; Department of Internal Medicine II, University Hospital of Würzburg, Würzburg.; Besse A

Subjects: Multiple Myeloma*/Multiple Myeloma*/Multiple Myeloma*/pathology; Humans ; Proteasome Endopeptidase Complex

• Source: Haematologica [Haematologica] 2023 Jun 01; Vol. 108 (6), pp. 1628-1639. Date of Electronic Publication: 2023 Jun 01.Publisher: Ferrata Storti Foundation Country of Publication: Italy NLM ID: 0417435 Publication Model: Electronic Cited Medium: Internet ISSN:

تفاصيل العنوان

BCMA loss in the epoch of novel immunotherapy for multiple myeloma: from biology to clinical practice.

• Authors : Zhou X; Department of Internal Medicine II, University Hospital of Würzburg, Würzburg.; Rasche L

Subjects: Multiple Myeloma*/Multiple Myeloma*/Multiple Myeloma*/drug therapy ; Receptors, Chimeric Antigen* ; Antibodies, Bispecific*/Antibodies, Bispecific*/Antibodies, Bispecific*/therapeutic use

• Source: Haematologica [Haematologica] 2023 Apr 01; Vol. 108 (4), pp. 958-968. Date of Electronic Publication: 2023 Apr 01.Publisher: Ferrata Storti Foundation Country of Publication: Italy NLM ID: 0417435 Publication Model: Electronic Cited Medium: Internet ISSN:

تفاصيل العنوان